The Application of Rho Kinase Inhibitors in the Management of Glaucoma

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Glaucoma is a leading cause of irreversible blindness globally, characterized by chronic neurodegeneration.
• Current treatments primarily aim to lower intraocular pressure (IOP), the sole modifiable risk factor.
• Existing therapies include beta-blockers, prostaglandin analogs, and carbonic anhydrase inhibitors, targeting aqueous humor production or uveoscleral outflow.

Purpose of the Study:

• To review the mechanisms of Rho kinase (ROCK) inhibitors in glaucoma treatment.
• To discuss their efficacy in reducing IOP, offering neuroprotection, and preventing fibrosis.
• To evaluate recent clinical trials and compare ROCK inhibitors with existing anti-glaucomatous medications.

Main Methods:

• Literature review of preclinical and clinical studies on ROCK inhibitors.
• Analysis of drug mechanisms targeting the trabecular meshwork outflow pathway.
• Comparative assessment of ROCK inhibitors against conventional glaucoma therapies.

Main Results:

• ROCK inhibitors represent a novel class of drugs with multifunctional therapeutic properties.
• They directly enhance trabecular meshwork outflow, leading to reduced IOP.
• Emerging evidence suggests potential neuroprotective and anti-fibrotic effects.

Conclusions:

• ROCK inhibitors demonstrate significant potential as a new therapeutic strategy for glaucoma.
• Their multifaceted mechanism offers advantages over traditional treatments.
• Further research and clinical trials are crucial to establish their long-term efficacy and safety profile.